Latest Insider Transactions at Fate Therapeutics Inc (FATE)
This section provides a real-time view of insider transactions for Fate Therapeutics Inc (FATE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of FATE THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of FATE THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2021
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+12.09%
|
$50,000
$2.73 P/Share
|
|
Dec 10
2021
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-0.82%
|
$390,000
$52.42 P/Share
|
|
Dec 10
2021
|
Yu Waye Chu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+5.33%
|
$120,000
$16.32 P/Share
|
|
Nov 19
2021
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+32.65%
|
-
|
|
Nov 19
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,540
+34.72%
|
-
|
|
Nov 19
2021
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,540
+37.9%
|
-
|
|
Nov 19
2021
|
Cindy Tahl General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+26.51%
|
-
|
|
Nov 19
2021
|
Bahram Valamehr Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+28.01%
|
-
|
|
Nov 19
2021
|
J Scott Wolchko President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
86,475
+15.26%
|
-
|
|
Nov 18
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-4.83%
|
$1,080,000
$54.27 P/Share
|
|
Nov 18
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$40,000
$2.7 P/Share
|
|
Oct 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$1,740,000
$58.88 P/Share
|
|
Oct 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.35%
|
$90,000
$3.42 P/Share
|
|
Oct 21
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-3.6%
|
$1,800,000
$60.23 P/Share
|
|
Oct 21
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Oct 01
2021
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
50,000
-11.87%
|
$2,900,000
$58.89 P/Share
|
|
Oct 01
2021
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+24.03%
|
$300,000
$6.55 P/Share
|
|
Sep 28
2021
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,460
-27.08%
|
$1,206,520
$62.53 P/Share
|
|
Sep 28
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,325
+19.43%
|
$606,375
$35.52 P/Share
|
|
Sep 13
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
25,000
-7.31%
|
$1,650,000
$66.75 P/Share
|
|
Sep 13
2021
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+17.15%
|
$50,000
$2.73 P/Share
|
|
Aug 19
2021
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,474
-2.03%
|
$305,712
$88.85 P/Share
|
|
Aug 19
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-4.83%
|
$1,760,000
$88.01 P/Share
|
|
Aug 19
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$80,000
$4.84 P/Share
|
|
Aug 03
2021
|
Yuan Xu |
BUY
Grant, award, or other acquisition
|
Direct |
4,744
+50.0%
|
-
|
|
Jul 23
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$2,550,000
$85.28 P/Share
|
|
Jul 23
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+3.46%
|
$90,000
$3.79 P/Share
|
|
Jul 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.4%
|
$2,580,000
$86.16 P/Share
|
|
Jul 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Jul 01
2021
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
55,534
-3.19%
|
$4,942,526
$89.97 P/Share
|
|
Jul 01
2021
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
55,534
+8.61%
|
$333,204
$6.04 P/Share
|
|
Jun 14
2021
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+50.0%
|
-
|
|
Jun 14
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
25,000
-7.29%
|
$2,225,000
$89.85 P/Share
|
|
Jun 14
2021
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+9.72%
|
$50,000
$2.82 P/Share
|
|
Jun 02
2021
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
John Mendlein |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+1.65%
|
-
|
|
Jun 02
2021
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Karin Jooss |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Robert S Epstein |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
William H Rastetter |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+4.34%
|
-
|
|
Jun 02
2021
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,681
+0.02%
|
-
|
|
May 20
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-4.83%
|
$1,540,000
$77.16 P/Share
|
|
May 20
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$80,000
$4.84 P/Share
|
|
Apr 23
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$2,550,000
$85.24 P/Share
|
|
Apr 23
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.35%
|
$120,000
$4.73 P/Share
|
|
Apr 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$2,550,000
$85.54 P/Share
|
|
Apr 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Apr 16
2021
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,275
-1.63%
|
$271,825
$83.04 P/Share
|